MHRAsafety guidance72% confidence
Guidance: AI Airlock Sandbox Phase 2 Programme Report
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Avidity Biosciences.
Regulatory Analysis
The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.
Supporting Context
- Therapeutic area
- Neurology · Duchenne Muscular Dystrophy
- Sub-indication
- General
Related signal: Managed Access Program for Del-zota in DMD Patients Announced by Avidity Biosciences